Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

295 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study.
Baldini C, Charton E, Schultz E, Auroy L, Italiano A, Robert M, Coquan E, Isambert N, Moreau P, Le Gouill S, Le Tourneau C, Ghrieb Z, Kiladjian JJ, Delord JP, Roca CG, Vey N, Barlesi F, Lesimple T, Penel N, Soria JC, Massard C, Besle S. Baldini C, et al. Among authors: kiladjian jj. ESMO Open. 2022 Jun;7(3):100468. doi: 10.1016/j.esmoop.2022.100468. Epub 2022 May 6. ESMO Open. 2022. PMID: 35533427 Free PMC article.
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Rea D, Jourdan E, Allard C, Delmer A, Rousselot P, Legros L, Berger M, Corm S, Etienne G, Roche-Lestienne C, Eclache V, Mahon FX, Guilhot F; SPIRIT Investigators; France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC). Preudhomme C, et al. N Engl J Med. 2010 Dec 23;363(26):2511-21. doi: 10.1056/NEJMoa1004095. N Engl J Med. 2010. PMID: 21175313 Free article. Clinical Trial.
A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors.
Teixeira L, Medioni J, Garibal J, Adotevi O, Doucet L, Durey MD, Ghrieb Z, Kiladjian JJ, Brizard M, Laheurte C, Wehbe M, Pliquet E, Escande M, Defrance R, Culine S, Oudard S, Wain-Hobson S, Doppler V, Huet T, Langlade-Demoyen P. Teixeira L, et al. Among authors: kiladjian jj. Clin Cancer Res. 2020 Feb 1;26(3):588-597. doi: 10.1158/1078-0432.CCR-19-1614. Epub 2019 Sep 26. Clin Cancer Res. 2020. PMID: 31558479
[An example of Clinical Investigations Center reorganization during the COVID-19 pandemic French national lockdown].
Ghrieb Z, Allaoua S, Huang J, Langner N, François F, Maréchal C, Jebali M, Lebbé C, Chellah A, Bergeron A, Kiladjian JJ, Daltro De Oliveira R, Soret-Dulphy J, Benajiba L. Ghrieb Z, et al. Among authors: kiladjian jj. Therapie. 2021 Jul-Aug;76(4):347-358. doi: 10.1016/j.therap.2021.02.003. Epub 2021 Feb 14. Therapie. 2021. PMID: 33640116 Free PMC article. French.
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.
Buske C, Dreyling M, Alvarez-Larrán A, Apperley J, Arcaini L, Besson C, Bullinger L, Corradini P, Giovanni Della Porta M, Dimopoulos M, D'Sa S, Eich HT, Foà R, Ghia P, da Silva MG, Gribben J, Hajek R, Harrison C, Heuser M, Kiesewetter B, Kiladjian JJ, Kröger N, Moreau P, Passweg JR, Peyvandi F, Rea D, Ribera JM, Robak T, San-Miguel JF, Santini V, Sanz G, Sonneveld P, von Lilienfeld-Toal M, Wendtner C, Pentheroudakis G, Passamonti F. Buske C, et al. Among authors: kiladjian jj. ESMO Open. 2022 Apr;7(2):100403. doi: 10.1016/j.esmoop.2022.100403. Epub 2022 Jan 28. ESMO Open. 2022. PMID: 35272130 Free PMC article.
Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.
Rey J, Viallard JF, Keddad K, Smith J, Wilde P, Kiladjian JJ; FOX study investigators. Rey J, et al. Among authors: kiladjian jj. Eur J Haematol. 2014 Feb;92(2):127-36. doi: 10.1111/ejh.12210. Epub 2013 Nov 25. Eur J Haematol. 2014. PMID: 24118452 Free PMC article. Clinical Trial.
Ruxolitinib for the treatment of patients with polycythemia vera.
Kiladjian JJ, Winton EF, Talpaz M, Verstovsek S. Kiladjian JJ, et al. Expert Rev Hematol. 2015 Aug;8(4):391-401. doi: 10.1586/17474086.2015.1045869. Epub 2015 May 17. Expert Rev Hematol. 2015. PMID: 25980454 Free PMC article. Review.
Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms.
Devillier R, Raffoux E, Rey J, Lengline E, Ronchetti AM, Sebert M, Boissel N, Robin M, Vey N, Kiladjian JJ, Dombret H, Cluzeau T. Devillier R, et al. Among authors: kiladjian jj. Br J Haematol. 2016 Feb;172(4):628-30. doi: 10.1111/bjh.13516. Epub 2015 Jun 10. Br J Haematol. 2016. PMID: 26061174 Free article. No abstract available.
295 results